All right. Good morning, everyone. Welcome to the Stifel Healthcare Conference. My name is Colleen Kusy. I am one of the senior analysts here covering biotech, and this morning, I am very happy to have with us the team from 4D Molecular Therapeutics, including CFO Kristian Humer and Chief Commercial and Business Officer Chris Simms. They will give a formal presentation, and then we will dive into some Q&A.
Awesome. Thank you, Colleen, and good morning. We appreciate the opportunity this morning to share the 4DMT story. My name is Chris Simms, as Colleen mentioned, the Chief Commercial and Business Officer. Just as a note, we may be making some forward-looking statements. More information can be found on our website or in our SEC filings. Some key takeaways for today. First of all, we are really excited at 4DMT with the progress that we have made on our lead program, 4D-150, which is going to take up pretty much the entire presentation today. We have other things in development, but most of our focus right now is on our lead program, 4D-150, and I think the reasons for that will be obvious as I go through the deck. 4D-150 is our lead retina program.
We believe it has the potential to establish a new treatment paradigm for the treatment of wet age-related macular degeneration. Some key reasons why we believe that to be possible. First of all, we are pursuing 4D-150 to be a backbone therapy with the potential for lifelong continuous disease control from a single intravitreal dose, an injection. Second, our target product profile, which we will review in a little more detail in a few slides, addresses what we view as the key unmet need of patients in this space, specifically the preservation of vision while reducing treatment burden, with the opportunity for some patients to be injection-free for a lifetime. As we will go through, that is quite a shift from current standard of care and what patients currently experience.
The third point is that our clinical trial data, our phase III design, and strong execution positions as well for success. I will touch a little bit more on that as well. The fourth point, really important when it comes to commercial adoption, is that patients, physicians, and payers together are expected to drive, we believe, robust and broad commercial adoption. We believe we have the possibility to address some really important unmet needs across all of these stakeholders, which ultimately will be the foundation for our commercial strategy. Sorry, FYI, the countdown clock is not moving, if that matters. Just as a reminder why we believe we are uniquely positioned to achieve this, let us take a look at the design of 4D-150. It is designed for a low-dose targeted delivery of aflibercept-producing transgenes to the retina with, again, a single intravitreal injection.
At the core to our product design is our vector. The R100 capsid was invented and developed at 4DMT. It is proprietary, and we believe that capsid allows us to be very unique in our approach to using the gene therapy for treating retinal disease. Specifically, the R100 vector allows us to do three things that are really important. First of all, it allows us to take a low-dose intravitreal injection approach. Second, it allows us to be targeted in the delivery to retinal tissue specifically. Third, we believe it has the potential for minimal toxicity and inflammation.
When we combine the R100 capsid with our payload, specifically the fact that it includes aflibercept, which is commonly known, of course, as EYLEA, which has been dosed in over 64 million eyes since it launched, we think the combination of that provides a direct retina-specific therapeutic effect that has the potential for lifelong expression for patients. Why is that important? Well, just take a moment to consider the biology of wet AMD. Wet AMD is a disease. It is chronic, it is variable, it is heterogeneous, it is always there. The current treatment paradigm today is episodic and finite with bolus injections. These bolus injections work really well. We see that when patients are diagnosed, they often get upfront loading doses of two or three injections, and then they are put on some sort of a schedule of extension based upon the need.
It could be a month, it could be every other month, based again on what the physician deems is appropriate. That creates an oscillation and a peak and trough in the treatment of the disease. The challenge with that is that you have a chronic always-on disease, and you have a treatment approach that is episodic. Again, you see those peaks and troughs. What that results in for many patients is, one, a significant treatment burden that is hard to maintain over time. That significant treatment burden often results in the lack of continuous disease control. For many patients, the combination of those two things means that over time, they actually lose vision, which is unfortunate because we know that these therapies, we know that VEGF suppression actually causes a patient to gain vision upon diagnosis.
However, the current bolus treatment approach often results in that vision being lost as patients are unable to sustain the treatment burden. We believe a better approach is a backbone therapy. With 4D-150, simply, we take a backbone therapy approach that we believe provides continuous disease control, and we match the therapy with the chronic nature of the disease. The potential for that is illustrated in this next slide, which is, we think it solves for what we refer to as the continuous control gap. The continuous control gap is simply this. As I mentioned, patients lose vision today on current bolus therapies. Despite gaining vision initially, the burden of treatment causes vision to be lost over time. We see that in the real world, somewhat regardless of the durability of the bolus therapy that patients are being treated with.
A big piece of development for a lot of new therapies that are trying to enter into this space is increasing the durability by increments. While we know that to be important, we have seen that with historical recent launches, none of these therapies offer the potential of continuous disease control for the life of the patient. We believe with 4D-150 as a backbone therapy, we could control or we could close that continuous control gap, thereby allowing patients the possibility of preserving vision for the rest of their lives, in addition to significantly reducing the burden of treatment. This slide recaps some results from our phase II trial that we've shared previously. Specifically, we look here at the 15 patients that are within the recently diagnosed population.
The reason we highlight that patient population being recently diagnosed is that they're most comparable to the patients that we're studying in our phase III program. I'll go through those details in a few minutes. What we see from our PRISM results is actually quite encouraging. Here we see on the left-hand side that out to two years, you see good steady control of central subfield thickness. It's a biomarker, in essence, for anatomical control. That's really important when it comes to treating this disease. Physicians often reference that as a marker for whether they retreat or not. We also see a nice continuous maintenance of visual acuity, as evidenced by the bottom left-hand chart. Back to the slide a couple of minutes ago where we said, closing that continuous control gap requires that you maintain vision to be steady over a long period of time.
We actually see that with our phase II results from PRISM. In addition, on the right-hand side, we've been able to deliver that in the context of significant treatment burden reduction. Specifically, again, over two years, patients got an average of 1.6 supplemental injections. If you compare that to what they would have received if they were being treated on-label with EYLEA at a Q8 week frequency, that's an 87% treatment burden reduction. Really importantly, 66% of those patients out to two years were injection-free. Of course, none of this matters if you don't have a safety profile that's acceptable. What we see with the 71 patients that have been treated with the phase III dose is a safety profile that's very encouraging. We had two cases of inflammation early on that were mild and transient and were resolved within the 20-week prophylactic steroid regimen that we administered.
After that 20-week period, we saw no cases of 4D-150-related inflammation events. Really importantly, there were no cases of serious adverse events observed at any time point. So no cases of occlusive or non-occlusive retinal vasculitis, choroidal effusions, or endophthalmitis, or hypotony. From a product profile standpoint, to summarize, 4D-150, we believe, is designed to achieve what we view as an ideal product profile that has the potential to be best in class for treating wet AMD by providing a backbone therapy and the possibility of continuous disease control. We've listed the five supporting elements that underpin that value proposition on the right. I won't take you through all of them, but I will point out at the bottom, it's a point I think worth reiterating, which is the fact that 4D-150 is designed to be delivered as a single in-office intravitreal injection.
The reason that's really important is that retina clinics are super busy. Often today, retina doctors are administering 50, 60, upwards of 80 bolus injections to patients in an injection clinic. Therefore, a product that fits seamlessly into that process is really important for real-world adoption. Further, the fact that it's a single intravitreal injection from a commercial perspective means that 4D-150 will be reimbursed, we believe, through the buy-and-bill reimbursement model, which is, of course, very familiar to retina clinics today. Just a couple of comments on our phase III program, 4FRONT-1 and 4FRONT-2, a global program designed for global approval. We've had great interaction and supportive interactions with regulatory agencies from the FDA and EMA, where we have RMAT and PRIME designations respectively. We've also had very productive interactions with PMDA.
Both trials are fully enrolled and again, powered for the stringent criteria of about four letters of difference in the non-inferiority of vision at week 52. A side note as well, as you'll see on this slide, the majority of patients in these trials are treatment-naive, with an exception of 4FRONT-2, where a portion can be treated up to a maximum of six months. That's really important because I think that's the first time that an intravitreal gene therapy has gone into, in essence, a frontline patient population. The fact that we were able to do that and we enrolled both trials within about a 12-month period, we think is a strong indication of the unmet need and the enthusiasm, both from physicians as well as patients. Just a couple of notes on the trial design.
Again, we'll point out that our phase III wet AMD trials are fairly standard designs, so we compare 4D-150 to an on-label control arm of aflibercept with a week 52 endpoint measuring non-inferiority in vision. It's important as well to highlight that we think we've optimized for the patient population. The two bottom green boxes that are highlighted there talks about how we believe we've done that. Specifically, we capped the entry criteria from an anatomical standpoint to 500 microns. In addition to that, we require that patients show at least a 15% reduction in CST or a complete resolution of retinal fluid to get randomized into our trial. That's important for a couple of reasons, but one of the key points is that we believe it helps protect vision, but also reduces variability in the dataset.
Of course, the other element of the design, which is fairly common, is that patients are eligible for supplemental treatment. What this slide shows is the criteria and the reference point that guides the supplemental treatment in our trial. I won't go through the details, but these criteria are very important. Certainly, they need to be clinically relevant, and we believe we've designed them for their primary goal of protecting vision, which is our primary endpoint. Clearly, you need to protect against vision first and foremost. Without that, treatment burden reduction is certainly not as relevant. So 2026 has been an exciting execution-focused year for us. As I just covered, we finished enrollment in our two phase III trials. We're really excited for 2027, where we have top-line readout on both 4FRONT-1 and 4FRONT-2.
4FRONT-1 is scheduled for readout of results in the second quarter, and 4FRONT-2 in the second half of 2027. Financially in a strong cash position, and with cash runway expected into the second half of 2028. Thank you for the opportunity, and thanks for the time.
Great. Thanks for that presentation, Chris. I know we don't have the clinical team here today, but maybe I'll jump off of some of the last comments you were talking about on the trial design to start. You really designed this study in a thoughtful way. Maybe if you could just kind of hit on again what you feel like you've done to increase the probability of success for these phase III trials.
Yeah. I'll maybe go into a little bit more detail, Colleen. It's a really important question. First of all, I'll point out again that our phase III trials are primarily a naive patient population, and that's important for a couple of reasons. One, it aligns with FDA guidance. The FDA requires that you show vision benefit in these trials, and showing a vision benefit, in essence, requires that you study patients that are naive, so therefore they have vision to gain. The other reason that's important for us is we saw clearly through our PRISM results, I just showed the recently diagnosed patient population, but we had a very impactful result across all patients through our phase II program, regardless of their disease severity. However, where we saw that result be most pronounced were in patients that were recently diagnosed.
In our PRISM study, that was measured by patients diagnosed within the prior six months. I think biologically, that makes sense as well, right? A more recently diagnosed patient has more healthy retinal cells, and therefore more healthy retinal tissue that we transduce with our product approach. I think those designs are really, really important. Then the design around what governs a retreatment is critical. I didn't go through the details in my presentation, but the high level is that to qualify for supplemental treatment in our trial, you need to hit a number of criteria. The first is a combination of showing a five-letter loss in addition to a 50-micron increase, or a 10-letter loss by itself, or a 100-micron increase in anatomy.
That's reference versus the average of vision at week four and eight, and the lowest point of anatomy, I think, after the first two loading doses. That's important because, one, it helps govern and I think reduce what we believe is variability in those results. But secondly, we think we've designed those supplemental criteria to protect against primarily our primary endpoint of vision. As I mentioned, first and foremost, hit your primary endpoint. If that means you sacrifice some retreatment and therefore a treatment burden reduction on the margins, we think that's acceptable. But you first got to, I think, design those criteria to protect against your primary endpoint.
Great. In terms of the rescue rate in the trial, what's kind of the expectation around what investors should be focused on?
Yeah. We hesitate to give a specific number because it becomes a binary conversation at that point. What I think is important to share is, we've shared through a number of different audiences the results we saw through our phase I/II PRISM study. The general summary of those treatment burden reduction rates, if you will, kind of fell into the 80%-90% range out to two years, dependent upon the patient population that you were looking at. Patients that were more severe, clearly the treatment burden reduction rate was a little bit lower there, I think in the mid to high 70s. Patients that were recently diagnosed, we saw treatment burden reduction rates in the high 80s. Then in conjunction with that, you saw treatment-free rates in the 40%, 50%, or 60% across those patient populations as well.
What I will tell you is that when we show those results to any retina physician anywhere in the world, they will tell us that's paradigm-shifting. Like, that's way beyond anything that's incremental in development and has the potential to completely change their practice and how they think about treating that disease. We don't think we have to be at that level, but certainly with the dataset that we've seen so far, we think we're well-positioned to be in that range or be in a range that's highly relevant.
Has the FDA given much guidance in terms of the retreatment criteria or how they view rescues in the context of this trial?
They have. I mean, we've shared, of course, our design with the FDA through our regulatory interactions. They've been supportive of our design. We haven't received any direction or feedback on it related to, I think sometimes the question comes up about the timing of retreatment relative to your primary endpoint. We haven't received that feedback, we think partly because we're not a finite treatment. I think other treatments that are designed to be six months or something in that range, that conversation we think is more relevant, where it's clear that those treatments are no longer present. We're not a finite treatment. We're lifelong, so therefore, I think the relevance of that is different for our approach.
Great. Can you also touch on the prophylactic steroid regimen in your phase IIIs and your confidence that the safety profile that you've seen before will be replicated?
Yeah. I think on safety, as you know, is super important, right? On any therapy, but certainly with the history of gene therapy, I think that's what most people pay attention to first and foremost, understandably so. I would say a couple things. I think first, we think our safety profile is driven by our science. I talked about the R100 vector. The fact that that vector has been selected to be very tissue-specific is really important because as I mentioned, that allows us, one, to take a low dose, and clearly there's evidence the more you push the dose, the more you run the risk of having potential safety events. So that's really important. It also means that we don't believe we're transducing cells, particularly in the anterior segment, that we shouldn't be. So therefore, we think that has implications for safety as well.
But in addition to that, out of an abundance of safety, as you referenced, we do have a 20-week prophylactic steroid regimen, which is very common in all of these trials. For us, it's a 20-week Durezol treatment. It's tapered over that 20-week period. I'll tell you, it's one of the questions that I certainly had upon when I joined 4D a couple years ago was what would be physician and patient receptivity to that? I've been blown away with the fact that I have yet to hear one physician that's in our clinical trials express any patient hesitancy about that treatment whatsoever. I think what they remind me of when I ask that question is, well, certainly that has some of the potential logistical challenges for patients, but a lot of these patients are used to taking topical drops for other reasons.
The possible benefit of reducing treatment burden by 80%, or for many patients, the potential of being treatment-free for the rest of their lives far outweighs any inconvenience that may be associated with a temporary topical steroid regimen. It's a bit of a side note, but I'll tell you one of the things, we talked about this at our recent investor day, one of the things that really is exciting for me from a commercial perspective is when we start to talk to patients about what a therapy like this would mean for them and their life, the anxiety it could reduce, the response we get is overwhelmingly positive.
We, again, somewhat tangential, but we think the patient interest and the potential of 4D-150 to have a significant effect on a patient's life, certainly, I think counterbalances any concern that folks may have about a temporary topical steroid regimen.
Great. We have a couple other gene therapy wet AMD treatments reading out in the next number of months here. Can you maybe just walk us through some of the differences we should be aware of between your trial design and some of the competing trial designs?
Yeah. Well, first of all, I think across retina overall, as you well know, there's a lot of things going on. That's not surprising, right? It's like, listen, it's a $16 billion category today. It's grown consecutively over the years, driven by an aging population, also driven by there has been new innovative therapies that have come to market. All of these therapies continue to pursue, at least the boldest ones, like increments of durability gain. Again, important, we saw with the VABYSMO benefit of maybe 10 to 14 days, and it became a $4 billion drug. So I'm not dismissing the importance of durability. It's critically important. However, we believe there's a new way to approach this. We're not trying to increase durability by a couple of weeks. We're trying to have a continuous disease control backbone therapy that matches the biology of wet AMD.
The other gene therapy programs are trying to do the same thing. We welcome that. I think it's good for patients, it's good for the overall space to see significant innovation come to bear. We clearly believe we have differences versus the other gene therapy programs. REGENXBIO, I think we expect data from their program later this year. We're rooting for them. We think it could be good proof- of- concept. The big difference there, though, is REGENXBIO is a program, it's a gene therapy delivered through a subretinal surgery. That is not I mentioned earlier how we can seamlessly, I think, integrate into current retina practices and their operations. A subretinal surgery does not do that. It's not necessarily convenient. It takes the physician out of the clinic and has to go into the OR.
I think it's great proof- of- concept, but clearly being intravitreally delivered and being able to administer it in a clinic, which is what they're used to doing multiple times a day right now, is, we believe, a key advantage. The other program is from Adverum/Lilly. They were acquired last year. Similar approach to ours in that it's intravitreal. However, a couple things I think that are a difference and of note, they take a very different high-dose approach versus us by orders of magnitude. We think they may have to just because their vector is different. It's not as tissue-specific as we are. I think a lot of the community is going to look closely at that data to see what the safety profile looks like. We referenced earlier some of the issues with gene therapy.
I think that program in particular has had a history of having some pretty severe inflammatory events. Whether they've solved for that or not, I think we'll see as we see the phase III data.
Great. You touched on this. This is a really busy marketplace. There's the first generations, there's the longer acting, there's the biosimilars that have come on, TKIs are in development, a number of other gene therapies. How do you see gene therapy fitting into the broader treatment paradigm within wet AMD?
Yeah, I appreciate the fact that it is a busy marketplace, but again, I'll point out, it's busy for a reason. It's busy because there's lots of value there, but it's also busy because despite it being a large market, there's still a lot of significant unmet need. The way we see our approach as being different is back to what I mentioned earlier. We're not a bolus therapy. We're not a finite therapy. We're not an increment of durability gain. We believe we can be a backbone therapy that provides 24/7 continuous disease control, and therefore matches the therapy with the biology of the disease. We think that's really relevant. Physicians tell us it's really relevant. Interestingly, sometimes people think about a gene therapy and they look at other gene therapies and other therapeutic areas, and we sometimes get lumped into that category.
We think we're different from that as well because, one, we're low dose, we're locally delivered, and the fact that we're specific to the retina means that from a dosing and an approach standpoint, we stand apart versus anything else that's being delivered. So, we think we have very clear differentiation. We think from a patient needs standpoint, this approach of a backbone therapy fits with what doctors will tell us would be the ideal approach for treating this disease. We don't think this is an approach that is going to be kind of used for just a small minority of patients. We actually think the question that I ask physicians more and more is less around, like, what are the patients you would use it for?
It's more around considering this profile and the potential of a safe, always-on backbone therapy, what patients would you not consider it for? There's some answers to that, but largely, I think the general feedback we get is there's a very real possibility that this therapy could be like a backbone basal type of approach for the majority of patients with wet AMD.
Great. I think, historically, there's been some investor pushback that, oh, in this market or in this disease, doctors are paid to inject, and you could be kind of taking away some of their patients. How have you kind of reached alignment, or you think you've reached alignment with the physicians in the clinics?
Right. It's a really important variable, of course, in the real world. Bolus anti-VEGF therapies, I've worked on them for 13, 14 years in different capacity. They're reimbursed through a buy-and-bill model. In essence, physicians purchase the medicine, they take responsibility for administering them, and then they get reimbursed with a profit margin attached to that, and that's become a pretty viable economic model. Sometimes the quick reaction when you hear 80% treatment burden reduction rates is, "Wow, you're going to reduce revenue by 80%." And we're like, "Well, not necessarily." First of all of the current reimbursement today is a function of the price of the medicine.
While we don't know what the price will be, it's way too early to kind of go into details on that, what we do know is that it's not going to be the price at a single bolus anti-VEGF. So it'll be higher than that by a certain amount. We'll see where that lands. But what that translates to for a clinic is that you get reimbursed on a higher-priced medicine, but you get that upfront. The value that upfront capture is really important. The other part of the economic equation is today, we didn't talk a lot about this, but you look at real-world data, over a five-year period, up to 60% of patients that started on therapy at time zero are no longer on therapy at year five. And that's value lost from a retina clinic standpoint.
If you're able to capture that again with a single therapy that's priced potentially over that, considering the value for that time window, that's a huge amount of incremental value for the clinic. The last point that I think is important, 40% of retina docs that we survey would tell you that today their clinic is at capacity. They have a hard time seeing additional patients. I personally experienced that. I launched, as you know, a medicine called IZERVAY for geographic atrophy. One of the challenges was how do you fit another bolus injection into a very busy clinic because of this capacity concern? We could reduce over time treatment rates the way that we just described. We think there's a direct effect on that as well, on the capacity constraints of a clinic, and that can free up a clinic to pursue different revenue opportunities.
We think the economic value proposition of 4D-150 is actually better than the current treatment paradigm, albeit recognizing that it's different.
Great. I know we're just about out of time here, unfortunately. So maybe if you just want to wrap it up, Kristian, what are the main reasons why investors should be paying attention to 4DMT over these next six to 12 months?
Look, fundamentally, it's what Chris said. I think we really do believe 4D-150 has the potential to change the treatment paradigm for these patients. And it's a big market. It's meaningful. It's going to impact patients, physicians, and the current landscape, and the current providers of wet AMD treatments because this has the potential to become the treatment of choice.
Okay, great. Thank you so much.
Thank you.
Thank you.